GenVec To Present At 2015 Stem Cell Meeting On The Mesa

GAITHERSBURG, Md., Sept. 30, 2015 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) announced that Douglas E. Brough, Ph.D., the company's chief scientific officer, will provide a brief review of GenVec's technology platform at the 2015 Stem Cell Meeting on the Mesa.  This presentation will include highlights of the differentiated performance characteristics seen with GenVec's gorilla and monkey adenovectors, which offer advantages for multiple disease-fighting strategies such as nucleic acid delivery, genome editing and stem cell therapy.

The presentation is scheduled for Wednesday, October 7, beginning at 5:15 p.m. PDT/8:15 p.m. EDT.  A live video webcast of all company presentations at the Stem Cell Meeting will be available at:  http://stemcellmeetingonthemesa.com/webcast during the proceedings.  In addition, GenVec will post a video replay of Dr. Brough's talk on the company website when it becomes available after the meeting concludes at www.genvec.com in the Investors & Media presentations collection.      

About GenVec

GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary adenovector gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. GenVec's lead product candidate, CGF166, is licensed to Novartis and is currently in a Phase 1/2 clinical study for the treatment of hearing loss and balance disorders. In addition to our internal and partnered pipeline, we also focus on opportunities to license our proprietary technology platform, including vectors and production cell lines, for the development and manufacture of therapeutics and vaccines to the biopharmaceutical industry. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including with respect to GenVec's hearing loss and balance disorders program are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, such as the failure of Novartis to advance GenVec's hearing loss and balance disorders program.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.

Contact:         
GenVec, Inc.                           
Rena Cohen                
(240) 632-5501                      
[email protected]

SOURCE GenVec, Inc.

Related Links

http://www.genvec.com